Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and ...

A new drug called amycretin has shown it can help reduce body weight in two early-phase clinical trials. The drug, which ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or ...

This would make amycretin a more effective than other weight loss drugs like Wegovy, where a trial found that patients lost ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

Novo Nordisk's experimental drug amycretin shows promising results in early trials, aiding significant weight loss in ...

Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for ...